

REVIEW ARTICLE

Mast Cells as Regulators of Skin Inflammation and Immunity

Ilkka T. HARVIMA¹ and Gunnar NILSSON²

¹Department of Dermatology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, and ²Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Mast cells are known to be the effector cells of immediate-type allergy, but experimental evidence obtained during the last decade has revealed their role in innate and acquired immunity. Upon activation mast cells can undergo an anaphylactic or piecemeal degranulation or degranulation-independent mediator secretion, resulting in rapid or slow release of soluble mediators, such as serine proteinases, histamine, lipid-derived mediators, cytokines, chemokines and growth factors. Mast cells can express different receptors and ligands on the cell surface, molecules that can activate the cells of the immune system, such as different subsets of T cells. All these mediators and cell surface molecules can promote inflammation in the skin. During the last years, a new role for mast cells has emerged; induction of tolerance or immunosuppression and interaction with regulatory T cells. However, the mechanisms that switch the pro-inflammatory function of mast cells to an immunosuppressive one are unknown. In this review, the immunoregulatory function of mast cells and its relation to skin inflammation are discussed. Key words: mast cell; mediator; skin; inflammation; immunosuppression.

(Accepted May 14, 2011.)

Acta Derm Venereol 2011; 91: XX–XX.

Ilkka T. Harvima, Department of Dermatology, Kuopio University Hospital, POB 1777, FIN-70211 Kuopio, Finland. E-mail: ilkka.harvima@kuh.fi

Mast cells have traditionally been known as “allergy” cells that cause the symptoms of immediate-type allergy and are typically located at sites where the host tissue can encounter external antigens, allergens, toxins and microbes, e.g. the upper dermal skin, respiratory tract and bowel mucosa (1). Even though the physiological role of mast cells is not clear, evidence obtained from mouse models suggests that mast cells are essentially involved in protecting the skin from severe bacterial and parasitic infections (2–4) and from severe venom reactions after insect stings and snake bites (5). In addition, mast cells regulate cutaneous wound healing after trauma (6, 7).

Mast cells in the human tissues can be classified into MC_{TC}, MC_T and MC_C subtypes based on their proteinase content: MC_{TC} cells contain tryptase, chymase, carboxypeptidase and a cathepsin G-like proteinase, MC_T cells contain only tryptase (8–10), and MC_C cells

show chymase and carboxypeptidase, but not tryptase (10). They all contain histamine. Almost all mast cells in the human skin belong to the MC_{TC} type, whereas MC_T cells predominate in the lung and bowel mucosa (8, 10). This suggests that the “C” type enzymes, chymase, carboxypeptidase and a cathepsin G-like proteinase, have a specific function in the skin after release from mast cells through degrading different proteins and peptides.

In a traditional model, mast cells are activated to degranulation and mediator release by an allergen that cross-links IgE molecules and their FcεRI receptors on the cell membrane. However, this is a highly simplified picture of the mast cell. Skin mast cells can express the FcγRI- and FcγRIIa-receptors and thereby be activated by IgG-dependent mechanisms (11, 12). In addition to the binding to cell surface immunoglobulin, foreign antigens, such as microbial products, can bind to a variety of toll-like receptors expressed on mast cells (13). Endogenous peptides and proteins can activate mast cells for mediator release, such as complement products C3a and C5a (14), neuropeptides including substance P and vasoactive intestinal peptide (VIP) (15), stem cell factor (SCF) (16), tumour necrosis factor (TNF) (17), tryptase (18), cathelicidin LL-37 (19), α-melanocyte-stimulating hormone (20) and corticotrophin-releasing hormone (21). Furthermore, human mast cells can express CD30 ligand, a member of the TNF superfamily, and the cells can be activated via the CD30 receptor to chemokine secretion by means of reverse signalling (22). It is noteworthy that mast cells can not only be activated to mediator release by a simple on–off mechanism, i.e. resting cell or rapid and extensive anaphylactic degranulation. It has long been known that mast cells can undergo slow and partial piecemeal degranulation (23). In addition, other secretion mechanisms have been described, such as exosome secretion (24), and selective degranulation-independent mediator secretion (21, 22). For example, the increased interstitial histamine concentration in the psoriatic plaque suggests elevated mast cell activity and degranulation in a chronic inflammation without anaphylactic activation and urticarial whealing (25, 26).

Even though mast cells are important in immediate-type allergy and are involved in physiological skin reactions to trauma and infection, they can affect the immune system, promote inflammation or even suppress it. Pre-formed mediators stored in the secretory granules

include different proteases, histamine, heparin proteoglycan, chondroitin sulphate E, acidic hydrolases, and various cytokines and growth factors. After activation, mast cells can secrete newly-synthesized mediators, including prostaglandin D₂, leukotriene C₄, and a range of cytokines, chemokines and growth factors. In addition, they can express cell membrane receptors and ligands. These molecules can modulate the immune system in the skin, e.g. in psoriasis, atopic dermatitis and epithelial cancers (1, 13, 27, 28). Therefore, the purpose of this review is to discuss the recent findings on the role of mast cells in skin inflammation and immunity. However, the anaphylactic aspects, urticaria or mastocytosis are not dealt with in the review.

ACCUMULATION OF MAST CELLS IN SKIN INFLAMMATION

The number of mast cells is increased in chronic skin inflammation, e.g. psoriasis, basal cell carcinoma and chronic ulcers. Furthermore, it is the MC_{TC} type of mast cell that is typically encountered just beneath the epidermis/epithelium, and sometimes even inside the epidermis (29–32). Intraepidermal mast cells have been found in other chronic inflammatory skin diseases showing epidermal proliferation (33, 34).

There are different possibilities for the activation and accumulation of mast cells during inflammation. The SCF, the ligand for the Kit receptor, is essential for the growth, migration, activation and survival of mast cells in different experimental models (35–41). In support of this, numerous SCF-positive cells have been detected in the psoriatic lesion, chronic ulcers and basal cell carcinoma (42–44), and even mast cells themselves can produce SCF (43, 45). Kit receptor is expressed by mast cells in the dermis and by melanocytes in the epidermis (42, 46). Furthermore, mast cells show increased Kit immunopositivity in the psoriatic lesion, chronic leg ulcers, and during skin wound healing (42). In addition, it is possible that the accumulation of mast cells is a result of the action of prosurvival proteins (47). Indeed, we have recently found that mast cells show increased levels of Bfl-1 immunoreactivity, an activation-induced prosurvival protein, in the lesional skin of psoriasis, atopic dermatitis and basal cell carcinoma (Ekoff et al., unpublished results).

The recruitment of mast cells and their haematopoietic progenitors from the blood circulation can be increased. This mechanism can be highlighted by the expression of several chemokine receptors on mast cells (27). Furthermore, SCF, TGF- β , RANTES and stromal cell-derived factor-1 α (CXCL-12) can efficiently induce migration of human mast cells *in vitro* (48–50). Hence, chemoattractants produced in the inflamed skin tissue and chemokine receptors produced by mast cells could explain mast cell accumulation, though it is not known to what extent mast cells express these receptors in the inflamed skin. In addition to the essential role of SCF, there are several other relevant factors that can modulate the development or survival of mast cells, including IL-3, IL-4, IL-5, IL-6 (35), IL-9 (51), thrombopoietin (52), nerve growth factor (53), and endothelial cells (54).

MAST CELL TRYPTASE AND CHYMASE AS REGULATORS OF SKIN INFLAMMATION

The major protein in mast cell granules, β -tryptase, is a trypsin-like serine proteinase, which has a ring-like tetrameric structure with four active centres facing towards the central oval pore. Based on this structure, tetrameric β -tryptase is resistant to the action of large endogenous protease inhibitors, and heparin is needed to stabilize the enzyme (55–58). In agreement with this resistance to protease inhibitors, tryptase has histochemically been detected as catalytically active on skin cryosections from inflamed skin (30, 31, 59).

The pathophysiological significance of β -tryptase is not clear. However, there are several experimental findings suggesting its role in the activation and recruitment of different cell types, including endothelial cells (60–63), peripheral blood mononuclear cells, T cells and neutrophils (64–66) (Table I). In animal models, tryptase injections induce accumulation of neutrophils, eosinophils and other cells of the immune system in the skin of guinea pigs (67). Interestingly, the PAR-2 receptor is expressed by human skin mast cells (18), and the percentage of mast cells showing PAR-2 is increased in the psoriatic lesion (68) suggesting a possibility for paracrine potentiation of inflammation. Furthermore, tryptase may promote neurogenic inflammation by activating PAR-2 on nerves leading to the release of neuropeptides substance P and calcitonin gene-related peptide (69, 70) (Table I).

Table I. Mast cell tryptase can have both stimulatory and inhibitory functions in skin inflammation

Stimulatory function	Inhibitory function
Stimulation of angiogenesis and MCP-1 and IL-8 in endothelial cells (60–63)	Cleavage of eotaxin and RANTES (81)
Activation of peripheral blood mononuclear cells and neutrophils for cytokine production (64–66)	Cleavage of neuropeptides VIP and CGRP (82–84)
Paracrine or autocrine activation of mast cells through PAR-2 (18, 68)	Cleavage of cathelicidin LL-37 (19)
Activation of nerves (69, 70) and keratinocytes (72–75) through PAR-2	
Activation of metalloproteinases MMP-3 and -9 (76–78) and pro-urokinase (79)	

MCP-1: Monocyte chemoattractant protein-1; IL-8: interleukin-8; VIP: vasoactive intestinal peptide; CGRP: calcitonin gene-related peptide; PAR-2: protease-activated receptor-2.

Tryptase can interact with the epidermis, since tryptase-positive mast cells are typically situated close to the psoriatic epidermis and tryptase degrades fibronectin in the basement membrane zone *ex vivo* (29, 30, 71). The enzyme may activate keratinocytes directly through activation of PAR-2 on their surface (72–75). Tryptase is able to activate metalloproteinases (76–78) and pro-urokinase (79), or it can function as a gelatinase (80). Thus, tryptase may make space for T cells and neutrophils in the extracellular matrix and basement membrane zone allowing their migration into the epidermis. In contrast to the stimulatory function, tryptase may also have inhibitory functions, since it can degrade chemokines, neuropeptides and cathelicidin LL-37 (19, 81–84) (Table I).

Human α -chymase is a chymotryptic serine proteinase that is stored in high quantities in mast cell secretory granules. Like tryptase, chymase also binds efficiently to heparin, but chymase-heparin proteoglycan complexes are larger in size and are situated in a different subregion of the granule from tryptase-heparin proteoglycan complexes (85, 86). Thus, tryptase can diffuse through the extracellular matrix, whereas chymase tends to remain at the activation site (87, 88). In contrast to tryptase, chymase is active in the absence of heparin, though heparin can regulate the interaction between the enzyme and its substrates/inhibitors (32, 89, 90). Another distinct difference is that endogenous protease inhibitors, such as α_1 -proteinase inhibitor (α_1 -PI), α_1 -antichymotrypsin (α_1 -AC) (91), α_2 -macroglobulin (92), secretory leukocyte proteinase inhibitor (90) and squamous cell carcinoma antigen-2 (93) can inactivate chymase. However, this may be a more complex interaction, since chymase can effectively degrade α_1 -PI and α_1 -AC (91). Thus, chymase activity is regulated by the plasma protease inhibitors α_1 -PI and α_1 -AC, which are even present in increased levels in mast cells in the inflamed skin, as shown histochemically, e.g. in psoriasis, atopic dermatitis (94), basal cell carcinoma (31) and cutaneous herpes zoster (59). It is probable that they also partially inactivate chymase in allergic skin wheal reaction (95).

Chymase can be a potent candidate in the recruitment of inflammatory cells, since human chymase injected into the skin of guinea pigs stimulates the accumulation of neutrophils and eosinophils (96), and it stimulates monocytes, neutrophils, lymphocytes and eosinophilic cells *in vitro* (97, 98). Chymase may promote inflammation indirectly as it has been shown to activate pro-IL-1 β to IL-1 β (99), pro-IL-18 to IL-18 (100), and to generate a potent chemoattractant, 31-amino acid endothelin-1, for neutrophils and monocytes (101). However, chymase may regulate inflammation by degrading IL-6 and IL-13, and to some extent IL-5 and TNF- α (102). Furthermore, chymase can degrade eotaxin (81) and neuropeptides substance P and VIP (82, 103). Chymase

is a potent enzyme, but the effect is dependent on the levels of enzymatically active chymase in inflamed skin, where increased levels of protease inhibitors can be detected. Chymase can affect the epidermis and induce blister formation in some conditions, since it detaches keratinocytes from substratum and degrades fibronectin (32, 104).

MAST CELLS STIMULATE THE CELLS OF THE IMMUNE SYSTEM

The close interaction between mast cells and T cells is now well-known, and mast cells can express soluble factors, cell surface molecules and co-stimulatory molecules, which can activate different subsets of T cells (13, 28, 105, 106). This stimulatory effect of mast cells on T cells is markedly dependent on soluble TNF- α , as well as on direct cell–cell interactions between mast cell OX40 ligand (OX40L) and T-cell OX40 receptor (106–108). Even though there are no data on the level of OX40L in mast cells in inflamed skin, mast cells are the predominant source of preformed TNF- α in normal skin (109), and along with increased mast cell numbers TNF- α -positive mast cells are increased in number in the lesional skin of psoriasis, atopic dermatitis and basal cell carcinoma (110, 111). In a recent study on co-cultures with mouse mast cells, effector T cells and regulatory T cells, concomitant influence of mast cell OX40L together with IL-6 from effector T cells induced reversal of regulatory T-cell-mediated suppression resulting in Th17 cell differentiation (112). In other experiments in mice, mast cells and mast cell-derived TNF- α enhanced antigen- and Th17 cell-dependent development of a neutrophil-rich inflammatory response in the airways (113) giving further support to the assumption that mast cells can promote Th17 cell-dependent inflammation *in vivo*. Neutrophil recruitment by mast cell TNF- α and MIP-2 has also been shown in a T-cell-dependent delayed-type hypersensitivity reaction in the skin of mice (114). Hence, OX40L on mast cells, together with TNF- α and IL-6, appear to be essential molecules in promoting tissue inflammation.

Mast cells can secrete other soluble cytokines that are relevant in chronic skin inflammation. In the psoriatic lesion, mast cells show increased levels of interferon- γ immunoreactivity and the cytokine associates with the Psoriasis Area and Severity Index. In contrast to psoriasis, mast cells in the atopic dermatitis lesions show elevated amounts of IL-4 immunoreactivity but are only weakly immunopositive for interferon- γ (115, 116). In addition, mast cell IL-4 has been shown to associate with the size of allergic skin prick-test wheal reaction and serum total IgE level in atopic subjects (117).

In addition to OX40L, mast cells have been shown to express another member of the TNF superfamily on

the cell surface, CD30L, which can activate CD30⁺ lymphoma cell lines *in vitro* (118). Activation of the CD30 receptor on T cells has previously been shown to lead to interferon- γ secretion in Th1 cell clones and IL-4 and IL-5 secretion in Th2 cell clones (119). In the lesional skin of psoriasis, atopic dermatitis and basal cell carcinoma, mast cells show increased levels of CD30L immunoreactivity. Furthermore, the number of cells with CD30 receptor is increased in the upper dermis of these lesions as well (22, 111). *In vitro* and *ex vivo* experiments demonstrated that mast cells can be induced by means of reverse signalling through CD30 ligand for chemokine expression, such as IL-8, MIP-1 α and MIP-1 β (22). Therefore, during the interaction between CD30 ligand on mast cells and CD30 receptor on T cells both cells are presumably activated in the inflamed skin lesion.

Mast cells can express several immunologically active molecules on the cell surface, which are related to T-cell activation through antigen presentation. For example, mast cells can express MHC class I and MHC class II and therefore act as antigen-presenting cells to T cells *in vitro* (28, 105). Moreover, human mast cells have been shown to express MHC class II and to present staphylococcal superantigens to CD4⁺ T-cell hybridomas, giving rise to T-cell activation (120). Interestingly, human cord blood-derived mast cells have been shown to bind and phagocytose several bacteria strains *in vitro*, such as *Staphylococcus aureus*, leading to death of bacteria and TNF- α secretion from mast cells (121).

The presence of co-stimulatory molecules is important for effective T-cell activation upon antigen presentation. In line with this requirement, mouse and human mast cells cultured *in vitro* can express CD80 and CD86, molecules that are essential in such a co-stimulation (120, 122). Human mast cells have, in fact, been shown to express a range of other cell surface molecules as well, such as the CD antigens and adhesion molecules ICAM-1, VLA-4, Mac-1 and to some extent LFA-1 (123, 124). The adhesion molecules, especially ICAM-1, can stimulate T cells, but mast cells are activated upon interaction with activated T cells resulting in enhanced mast cell degranulation, migration and adhesion to extracellular matrix and endothelial cell ligands (125).

Like professional antigen presenting cells, mast cells can have the capability of migration to lymph nodes as evidenced by several experimental findings. For example, mouse experiments have shown that during dinitrofluorobenzene-induced contact hypersensitivity mast cells are activated and the cells migrate to draining lymph nodes where they can mediate T-cell recruitment (126). In addition to mast cells, mast cell mediators can diffuse to lymph nodes. For example, activation of mast cells in mouse footpad by injection of *Escherichia coli* or compound 48/80 resulted in rapid draining of mast cell-derived preformed TNF- α to lymph nodes where

it induced hypertrophy and recruitment of circulating T cells (127). Further complexity provides the study by Jawdat et al. (128), who demonstrated that the lymph node activation in mice can be mast cell TNF- α -dependent in an allergic response or TNF- α -independent in a response to the injection of bacterial peptidoglycan.

Mast cells and their mediators can activate professional antigen presenting cells, Langerhans' cells and dendritic cells for migration. In a mouse model, mast cell activation in ear pinna induced by an IgE-dependent mechanism or by bacterial peptidoglycan was crucially involved in Langerhans' cell migration to draining lymph nodes (128). In another mouse model of FITC-induced contact hypersensitivity in ear pinna, mast cells and their TNF- α were essential for optimal migration of dendritic cells to local lymph nodes (129). Interestingly, mast cells can release exosomes that harbour exogenous antigens. These exosomes can stimulate maturation of mouse dendritic cells leading to enhanced antigen presentation to T cells (24). Furthermore, histamine can play a role in the activation of antigen presenting cells, as shown in co-cultures of *in vitro*-developed human mast cells and monocyte-derived dendritic cells. In this work, mast cells were activated by Fc ϵ RI cross-linking, which then induced maturation of dendritic cells. These cells in turn induced polarization of naïve T cells towards Th2 lineage, and the effect was largely dependent on histamine and mast cell-dendritic cell contacts (130). In fact, the stimulation of histamine receptor H1 on dendritic cells leads to the production of proinflammatory cytokines, Th1 priming and increased antigen presenting activity, but the stimulation of H2 receptor favours IL-10 induction and Th2 or tolerance priming (131).

MAST CELLS AS SUPPRESSORS OF THE IMMUNE SYSTEM

Mast cells can be involved in the induction of tolerance or immunosuppression (105). For example, mast cells induce regulatory T-cell-dependent peripheral tolerance in a mouse model of skin allografts, and this reaction is related to the production of IL-9 from activated regulatory T cells (132). However, this tolerance to skin allografts in mice can be reversed by intragraft or systemic mast cell degranulation, giving rise to acute T-cell-dependent rejection and loss of the suppressive functions of regulatory T cells (133). The interesting role of IL-9, a mast cell growth and activation factor, has recently been shown in another mouse model, too. In this work on nephrotoxic serum nephritis model in mice, regulatory T cells, IL-9 secreted from them, and mast cells recruited by them into kidney-draining lymph nodes were crucial for nephroprotective and anti-inflammatory effects (134). In a recent study with

mouse cells *in vitro*, bone marrow-derived mast cells could induce increased percentage of CD4⁺, CD25⁺, FoxP3⁺ regulatory T cells from isolated spleen T cells and this induction was partially inhibited by a neutralizing anti-TGF- β 1 antibody in the co-culture system (135). On the other hand, Fc ϵ R-activated bone marrow-derived mouse mast cells can inhibit through H1 receptor the suppressive function of mouse CD4⁺, CD25⁺, FoxP3⁺ regulatory T cells over responder T cells (136).

Previously, mast cells have been thought to be proinflammatory in models of contact hypersensitivity, but this is not always the case. Interestingly, in a mouse model of contact hypersensitivity and using prolonged monitoring for up to 15 days after challenge, mast cells were shown to limit the inflammatory skin reaction by producing the immunosuppressive cytokine IL-10. Furthermore, mast cells were able to attenuate the mouse skin reactions induced by multiple challenges with ultraviolet irradiation for up to 30 days (137). One possible mechanism for this UV-induced immunosuppression has recently been clarified in this mouse skin model: chronic low-dose UVB irradiations induce the production of 1 α , 25-dihydroxyvitamin D₃, which, in turn, stimulates the corresponding vitamin D receptor on mast cells, resulting in IL-10 secretion and immunosuppression, but other mechanisms may also be involved (138). In addition, immunosuppression of mouse skin contact hypersensitivity reaction by UV-irradiation can be dependent on CXCR4-positive mast cells, which migrate from the skin to the B-cell area of draining lymph node caused by the action of the chemoattractant CXCL-12 (139). Interestingly, the interaction between mast cell CXCR4 and CXCL-12, are important in the suppression of contact hypersensitivity reaction in mouse skin, an immunosuppression, which was induced by the application of the organic chemical mixture, JP-8 jet propulsion fuel, onto the mouse skin (140). The role of IL-10 has been described in another mouse skin model, where mast cells and concomitant IL-10 expression in lymph nodes were critical intermediaries in the mosquito bite-induced suppression of delayed-type hypersensitivity reaction (141). Mast cell IL-10 induced by UV irradiation may not only inhibit cellular delayed-type hypersensitivity, but it can inhibit humoral immune responses. This possible mechanism was demonstrated recently by showing that UV irradiation of mouse skin blocks germinal centre formation in draining lymph nodes, antibody secretion, and T follicular helper cell function. IL-10 derived from mast cells was found to be an essential factor in these events and IL-10⁺ mast cells were detected in the draining lymph nodes 24 h after UV irradiation (142). Human mast cells have been shown to express IL-10 (143) and TGF- β (144). Hence, these cytokines may act in human skin to modify immune responses, though it is not known to what extent they are expressed in mast cells in diseased human skin.

In addition, IL-10 released from human mast cells can have the capability of inhibiting mast cell function in an autocrine or paracrine fashion (145).

Mast cells are typically increased in number in different cutaneous malignancies and they are assumed to participate in skin carcinogenesis by different mechanisms, such as immunomodulation, induction of angiogenesis, degradation of the extracellular matrix components, and promotion of tumour cell mitosis. The development of skin carcinomas requires malignant transformation and compromised immune system (146). UV irradiation is the major causative factor for skin carcinogenesis and mast cells evidently have a role in UV-induced immunosuppression using different mechanisms (137–139, 142, 146). The recruitment of immunomodulatory or immunosuppressive mast cells to the skin tumour may be due to carcinoma cell-derived SCF and Kit receptor on mast cells (42, 43, 111). There is recent experimental evidence to support this mechanism. First, in a mouse model of hepatocarcinoma SCF from tumour cells promoted the recruitment of injected bone marrow-derived mast cells to the tumour. On the other hand, activated mast cells were shown to release adenosine, which inhibited effector T cells and natural killer cells, and immunosuppression was enhanced by the increased presence of FoxP3⁺ regulatory T cells in the tumour (147). Secondly, in this same mouse hepatocarcinoma model, injected mast cells induced the SCF/Kit-dependent appearance of GR-1⁺, CD11b⁺ myeloid-derived suppressor cells. In addition, regulatory T cells increased in the tumour and showed increased expression of ectoenzymes CD39 and CD73, molecules, which in turn can produce inhibitory adenosine from ATP. Furthermore, regulatory T cells produced IL-9, which was essential for the tumour-promoting effects and survival time of mast cells (148). Nevertheless, the interaction between mast cells and regulatory T cells in cancer may be complex. Recently, in human colorectal cancer and murine polyposis it was demonstrated that




Fig. 1. A hypothetical model for the function of mast cells as proinflammatory or immunosuppressive cells in skin inflammatory diseases.

this interaction can lead to mast cell-induced generation of proinflammatory regulatory T cells without losing their T-cell-suppressive properties (149). This finding may support the concept that a cancer is often characterized by inflammation and peritumoural inflammatory cells, but sufficient immunosuppression is required to prevent excessive inflammation and harmful damage to the tumour.

CONCLUSION

Current knowledge indicates that mast cells are involved in chronic skin inflammatory diseases. A range of different factors is known to activate mast cells, and subsequently these cells can release rapidly or slowly effective preformed and newly-synthesized soluble mediators. Furthermore, mast cells can express cell surface ligands and receptors, and all these different mediators and cell surface molecules can be either proinflammatory or immunosuppressive (Fig. 1). Mast cells can potentially recruit the cells of the immune system, e.g. T cells, neutrophils and eosinophils, to the site of skin inflammation, and mast cells can stimulate the maturation of Langerhans' cells and dendritic cells and their migration to lymph nodes. Moreover, mast cells are capable of migrating to draining lymph nodes and activating the immune cells within them. Mast cells show plasticity in the expression of cytokines and TNF family ligands in skin inflammatory diseases, such as psoriasis, atopic dermatitis and basal cell carcinoma. New exciting functions for mast cells have emerged during recent years – induction of tolerance or immunosuppression, and protection from infections and toxins. However, the current evidence comes mostly from cell culture and animal models and further studies are required to verify the situation in humans. Further research is required into the mechanisms that switch proinflammation to immunosuppression or vice versa (Fig. 1).

ACKNOWLEDGEMENTS

The authors wish to thank the strategic funding of the Cancer Center of Eastern Finland and University of Eastern Finland, the COST Action BM1007 (Mast cells and basophils – targets for innovative therapies), the EVO-funding of Kuopio University Hospital, and MacNet (Mast Cell Network) funded by Swedish Research Council.

REFERENCES

- Harvima IT, Nilsson G, Suttle M-M, Naukkarinen A. Is there a role for mast cells in psoriasis? *Arch Dermatol Res* 2008; 300: 461–478.
- Maurer M, Lopez Kostka S, Siebenhaar F, Moelle K, Metz M, Knop J, et al. Skin mast cells control T cell-dependent host defense in *Leishmania* major infections. *FASEB J* 2006; 20: 2460–2467.
- Siebenhaar F, Syska W, Weller K, Magerl M, Zuberbier T, Metz M, et al. Control of *Pseudomonas aeruginosa* skin infections in mice is mast cell-dependent. *Am J Pathol* 2007; 170: 1910–1916.
- Metz M, Magerl M, Kühl NF, Valeva A, Bhakdi S, Maurer M. Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. *Exp Dermatol* 2008; 18: 160–166.
- Metz M, Piliponsky AM, Chen C-C, Lammell V, Åbrink M, Pejler G, et al. Mast cells can enhance resistance to snake and honeybee venoms. *Science* 2006; 313: 526–530.
- Huttunen M, Aalto M-L, Harvima RJ, Horsmanheimo M, Harvima IT. Alterations in mast cells showing tryptase and chymase activity in epithelializing and chronic wounds. *Exp Dermatol* 2000; 9: 258–265.
- Weller K, Foitzik K, Paus R, Syska W, Maurer M. Mast cells are required for normal healing of skin wounds in mice. *FASEB J* 2006; 20: 2366–2368.
- Irani A-MA, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. *J Histochem Cytochem* 1989; 37: 1509–1515.
- Schechter NM, Irani A-MA, Sprows JL, Abernethy J, Wintroub B, Schwartz LB. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell. *J Immunol* 1990; 145: 2652–2661.
- Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites: fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. *Path Res Pract* 1993; 189: 156–162.
- Zhao W, Kepley CL, Morel PA, Okumoto LM, Fukuoka Y, Schwartz LB. FcγRIIa, not FcγRIIb, is constitutively and functionally expressed on skin-derived human mast cells. *J Immunol* 2006; 177: 694–701.
- Tkaczyk C, Okayama Y, Woolhiser MR, Hagaman DD, Gilfillan AM, Metcalfe DD. Activation of human mast cells through the high affinity IgG receptor. *Mol Immunol* 2001; 38: 1289–1293.
- Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. *Curr Opin Immunol* 2007; 19: 31–38.
- el-Lati SG, Dahinden CA, Church MK. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. *J Invest Dermatol* 1994; 102: 803–806.
- Church MK, Lowman MA, Rees PH, Benyon RC. Mast cells, neuropeptides and inflammation. *Agents Actions* 1989; 27: 8–16.
- Dvorak AM, Costa JJ, Monahan-Earley RA, Fox P, Galli SJ. Ultrastructural analysis of human skin biopsy specimens from patients receiving recombinant human stem cell factor: subcutaneous injection of rhSCF induces mast cell degranulation and granulocyte recruitment at the injection site. *J Allergy Clin Immunol* 1998; 101: 793–806.
- van Overveld FJ, Jorens PG, Rampart M, de Backer W, Vermeire PA. Tumour necrosis factor stimulates human skin mast cells to release of histamine and tryptase. *Clin Exp Allergy* 1991; 21: 711–714.
- Moormann C, Artuc M, Pohl E, Varga G, Buddenkotte J, Vergnolle N, et al. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. *J Invest Dermatol* 2006; 126: 746–755.
- Schiemann F, Brandt E, Gross R, Lindner B, Mittelstädt J, Sommerhoff CP, et al. The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4. *J Immunol* 2009; 183:

- 2223–2231.
20. Grützkau A, Henz BM, Kirchhof L, Luger T, Artuc M. α -Melanocyte stimulating hormone acts as a selective inducer of secretory functions in human mast cells. *Biochem Biophys Res Commun* 2000; 278: 14–19.
 21. Cao J, Cetrulo CL, Theoharides TC. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. *Mol Pharmacol* 2006; 69: 998–1006.
 22. Fischer M, Harvima IT, Carvalho RFS, Möller C, Naukarinen A, Enblad G, et al. Mast cell CD30 ligand is up-regulated in cutaneous inflammations and mediates degranulation-independent chemokine secretion. *J Clin Invest* 2006; 116: 2748–2756.
 23. Dvorak AM, Kissell S. Granule changes of human skin mast cells characteristic of piecemeal degranulation and associated with recovery during wound healing in situ. *J Leukoc Biol* 1991; 49: 197–210.
 24. Skokos D, Goubran Botros H, Demeure C, Morin J, Peronet R, Birkenmeier G, et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. *J Immunol* 2003; 170: 3037–3045.
 25. Krogstad AL, Lönnroth P, Larson G, Wallin BG. Increased interstitial histamine concentration in the psoriatic plaque. *J Invest Dermatol* 1997; 109: 632–635.
 26. Petersen LJ, Hansen U, Kristensen JK, Nielsen H, Skov PS, Nielsen HJ. Studies on mast cells and histamine release in psoriasis: the effect of ranitidine. *Acta Derm Venereol* 1998; 78: 190–193.
 27. Juremalm M, Nilsson G. Chemokine receptor expression by mast cells. *Chem Immunol Allergy* 2005; 87: 130–144.
 28. Sayed BA, Brown MA. Mast cells as modulators of T-cell responses. *Immunol Rev* 2007; 217: 53–64.
 29. Harvima IT, Naukarinen A, Harvima RJ, Horsmanheimo M. Enzyme- and immunohistochemical localization of mast cell tryptase in psoriatic skin. *Arch Dermatol Res* 1989; 281: 387–391.
 30. Harvima IT, Naukarinen A, Paukkonen K, Harvima RJ, Aalto M-L, Schwartz LB, et al. Mast cell tryptase and chymase in developing and mature psoriatic lesions. *Arch Dermatol Res* 1993; 285: 184–192.
 31. Diaconu N-C, Kaminska R, Naukarinen A, Harvima RJ, Harvima IT. The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma. *J Eur Acad Dermatol Venereol* 2007; 21: 908–915.
 32. Huttunen M, Harvima IT. Mast cell tryptase and chymase in chronic leg ulcers: chymase is potentially destructive to epithelium and is controlled by proteinase inhibitors. *Br J Dermatol* 2005; 152: 1149–1160.
 33. Green RM, Cordero A, Winkelmann RK. Epidermal mast cells. *Arch Dermatol* 1977; 113: 166–169.
 34. Bolton LL, Montagna W. Mast cells in human ulcers. *Am J Dermatopathol* 1993; 15: 133–138.
 35. Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, Uzumaki H, et al. Effects of T-helper 2-type cytokines, interleukins-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. *Blood* 1995; 86: 3705–3714.
 36. Nilsson G, Blom T, Harvima I, Kusche-Gullberg M, Nilsson K. Stem cell factor-dependent human cord blood derived mast cells express α - and β -tryptase, heparin and chondroitin sulphate. *Immunology* 1996; 88: 308–314.
 37. Möller C, Alfredsson J, Engström M, Wootz H, Xiang Z, Lennartsson J, et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. *Blood* 2005; 106: 1330–1336.
 38. Frenzy AM, Gibbs BF, Pearce FL. The effect of recombinant stem cell factor on human skin and lung mast cells and basophil leukocytes. *Inflamm Res* 1997; 46: 35–39.
 39. Kambe N, Kambe M, Kochan JP, Schwartz LB. Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. *Blood* 2001; 97: 2045–2052.
 40. Costa JJ, Demetri GD, Harrant TJ, Dvorak AM, Hayes DF, Merica EA, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. *J Exp Med* 1996; 183: 2681–2686.
 41. Waskow C, Bartels S, Schlenner SM, Costa C, Rodewald H-R. Kit is essential for PMA-inflammation-induced mast-cell accumulation in the skin. *Blood* 2007; 109: 5363–5370.
 42. Huttunen M, Naukarinen A, Horsmanheimo M, Harvima IT. Transient production of stem cell factor in dermal cells but increasing expression of Kit receptor in mast cells during normal wound healing. *Arch Dermatol Res* 2002; 294: 324–330.
 43. Yamamoto T, Katayama I, Nishioka K. Expression of stem cell factor in basal cell carcinoma. *Br J Dermatol* 1997; 137: 709–713.
 44. Yamamoto T, Katayama I, Nishioka K. Possible contribution of stem cell factor in psoriasis vulgaris. *J Dermatol Sci* 2000; 24: 171–176.
 45. Zhang S, Anderson DF, Bradding P, Coward WR, Baddeley SM, MacLeod JD, et al. Human mast cells express stem cell factor. *J Pathol* 1998; 186: 59–66.
 46. Hjertson M, Kivinen PK, Dimberg L, Nilsson K, Harvima IT, Nilsson G. Retinoic acid inhibits in vitro development of mast cells but has no marked effect on mature human skin tryptase- and chymase-positive mast cells. *J Invest Dermatol* 2003; 120: 239–245.
 47. Xiang Z, Ahmed AA, Möller C, Nakayama K, Hatakeyama S, Nilsson G. Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation. *J Exp Med* 2001; 194: 1561–1569.
 48. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. *J Immunol* 1994; 153: 3717–3723.
 49. Juremalm M, Hjertson M, Olsson N, Harvima I, Nilsson K, Nilsson G. The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand stromal cell-derived factor-1 α acts as a mast cell chemotaxin. *Eur J Immunol* 2000; 30: 3614–3622.
 50. Olsson N, Piek E, ten Dijke P, Nilsson G. Human mast cell migration in response to members of the transforming growth factor- β family. *J Leukoc Biol* 2000; 67: 350–356.
 51. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. *J Immunol* 2003; 170: 3461–3467.
 52. Sawai N, Koike K, Mwamtemi HH, Kinoshita T, Kurokawa Y, Sakashita K, et al. Thrombopoietin augments stem cell factor-dependent growth of human mast cells from bone-marrow multipotential hematopoietic progenitors. *Blood* 1999; 93: 3703–3712.
 53. Kanbe N, Kurosawa M, Miyachi Y, Kanbe M, Saitoh H, Matsuda H. Nerve growth factor prevents apoptosis of cord blood-derived human cultured mast cells synergis-

- tically with stem cell factor. *Clin Exp Allergy* 2000; 30: 1113–1120.
54. Mierke CT, Ballmaier M, Werner U, Manns MP, Welte K, Bischoff SC. Human endothelial cells regulate survival and proliferation of human mast cells. *J Exp Med* 2000; 192: 801–811.
 55. Harvima RJ, Harvima IT, Dull D, Dunder UK, Schwartz LB. Identification and characterization of multiple forms of tryptase from human mast cells. *Arch Dermatol Res* 1999; 291: 73–80.
 56. Pereira PJB, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, et al. Human β -tryptase is a ring-like tetramer with active sites facing a central pore. *Nature* 1998; 392: 306–311.
 57. Hallgren J, Estrada S, Karlson U, Alving K, Pejler G. Heparin antagonists are potent inhibitors of mast cell tryptase. *Biochemistry* 2001; 40: 7342–7349.
 58. Schechter NM, Choi E-J, Selwood T, McCaslin DR. Characterization of three distinct catalytic forms of human tryptase- β : their interrelationships and relevance. *Biochemistry* 2007; 46: 9615–9629.
 59. Kaminska R, Harvima IT, Naukkarinen A, Nilsson G, Horsmanheimo M. Alterations in mast cell proteinases and protease inhibitors in the progress of cutaneous herpes zoster infection. *J Pathol* 1996; 180: 434–440.
 60. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, et al. Human mast cells stimulate vascular tube formation: tryptase is a novel, potent angiogenic factor. *J Clin Invest* 1997; 99: 2691–2700.
 61. Compton SJ, Cairns JA, Holgate ST, Walls AF. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1 β and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. *J Immunol* 1998; 161: 1939–1946.
 62. Compton SJ, Cairns JA, Holgate ST, Walls AF. Human mast cell tryptase stimulates the release of an IL-8-dependent neutrophil chemotactic activity from human umbilical vein endothelial cells (HUVEC). *Clin Exp Immunol* 2000; 121: 31–36.
 63. Kinoshita M, Okada M, Hara M, Furukawa Y, Matsumori A. Mast cell tryptase in mast cell granules enhances MCP-1 and interleukin-8 production in human endothelial cells. *Arterioscler Thromb Vasc Biol* 2005; 25: 1858–1863.
 64. Malamud V, Vaankin A, Abramsky O, Mor M, Burgess LE, Ben-Yehudah A, et al. Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF- α , IL-6 and IL-1 β : possible relevance to multiple sclerosis. *J Neuroimmunol* 2003; 138: 115–122.
 65. Wang H, He S. Induction of lactoferrin and IL-8 release from human neutrophils by tryptic enzymes via proteinase activated receptor-2. *Cell Biol Int* 2006; 30: 688–697.
 66. Li T, He S. Induction of IL-6 release from human T cells by PAR-1 and PAR-2 agonists. *Immunol Cell Biol* 2006; 84: 461–466.
 67. He S, Peng Q, Walls AF. Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. *J Immunol* 1997; 159: 6216–6225.
 68. Carvalho RF, Nilsson G, Harvima IT. Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. *Exp Dermatol* 2010; 19: 117–122.
 69. Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. *J Neurosci* 2003; 23: 6176–6180.
 70. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nat Med* 2000; 6: 151–158.
 71. Kaminska R, Helisalmi P, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. Focal dermal-epidermal separation and fibronectin cleavage in basement membrane by human mast cell tryptase. *J Invest Dermatol* 1999; 113: 567–573.
 72. Schechter NM, Brass LF, Lavker RM, Jensen PJ. Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts. *J Cell Physiol* 1998; 176: 365–373.
 73. Sharlow ER, Paine CS, Babiarz L, Eisinger M, Shapiro S, Seiberg M. The protease-activated receptor-2 upregulates keratinocyte phagocytosis. *J Cell Sci* 2000; 113: 3093–3101.
 74. Buddenkotte J, Stroh C, Engels IH, Moormann C, Shpacovitch VM, Seeliger S, et al. Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. *J Invest Dermatol* 2005; 124: 38–45.
 75. Hou L, Kapas S, Cruchley AT, Macey MG, Harriott P, Chinni C, et al. Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. *Immunology* 1998; 94: 356–362.
 76. Lohi J, Harvima I, Keski-Oja J. Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. *J Cell Biochem* 1992; 50: 337–349.
 77. Gruber BL, Marchese MJ, Suzuki K, Schwartz LB, Okada Y, Nagase H, Ramamurthy NS. Synovial procollagenase activation by human mast cell tryptase: dependence upon matrix metalloproteinase 3 activation. *J Clin Invest* 1989; 84: 1657–1662.
 78. Iddamalagoda A, Le QT, Ito K, Tanaka K, Kojima H, Kido H. Mast cell tryptase and photoaging: possible involvement in the degradation of extra cellular matrix and basement membrane proteins. *Arch Dermatol Res* 2008; 300 (suppl 1): S69–S76.
 79. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). *J Biol Chem* 1994; 269: 9416–9419.
 80. Fajardo I, Pejler G. Human mast cell β -tryptase is a gelatinase. *J Immunol* 2003; 171: 1493–1499.
 81. Pang L, Nie M, Corbett L, Sutcliffe A, Knox AJ. Mast cell β -tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities. *J Immunol* 2006; 176: 3788–3795.
 82. Franconi GM, Graf PD, Lazarus SC, Nadel JA, Caughey GH. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the Ferret. *J Pharmacol Exp Ther* 1989; 248: 947–951.
 83. Tam EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase. *Am J Respir Cell Mol Biol* 1990; 3: 27–32.
 84. Walls AF, Brain SD, Desai A, Jose PJ, Hawkings E, Church MK, et al. Human mast cell tryptase attenuates the vasodilator activity of calcitonin gene-related peptide. *Biochem Pharmacol* 1992; 43: 1243–1248.
 85. Goldstein SM, Leong J, Schwartz LB, Cooke D. Protease composition of exocytosed human skin mast cell protease-proteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. *J Immunol* 1992; 148: 2475–2482.

86. Whitaker-Menezes D, Schechter NM, Murphy GF. Serine proteinases are regionally segregated within mast cell granules. *Lab Invest* 1995; 72: 34–41.
87. Kivinen PK, Kaminska R, Naukkarinen A, Harvima RJ, Horsmanheimo M, Harvima IT. Release of soluble tryptase but only minor amounts of chymase activity from cutaneous mast cells. *Exp Dermatol* 2001; 10: 246–255.
88. Kivinen PK, Nilsson G, Naukkarinen A, Harvima IT. Mast cell survival and apoptosis in organ-cultured human skin. *Exp Dermatol* 2003; 12: 53–60.
89. Sayama S, Iozzo RV, Lazarus GS, Schechter NM. Human skin chymotrypsin-like proteinase chymase: subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans. *J Biol Chem* 1987; 262: 6808–6815.
90. Walter M, Plotnick M, Schechter NM. Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin. *Arch Biochem Biophys* 1996; 327: 81–88.
91. Schechter NM, Sprows JL, Schoenberger OL, Lazarus GS, Cooperman BS, Rubin H. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. *J Biol Chem* 1989; 264: 21308–21315.
92. Walter M, Sutton RM, Schechter NM. Highly efficient inhibition of human chymase by $\alpha(2)$ -macroglobulin. *Arch Biochem Biophys* 1999; 368: 276–284.
93. Schick C, Kamachi Y, Bartuski AJ, Çataltepe S, Schechter NM, Pemberton PA, et al. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. *J Biol Chem* 1997; 272: 1849–1855.
94. Harvima IT, Haapanen L, Ackermann L, Naukkarinen A, Harvima RJ, Horsmanheimo M. Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions. *Acta Derm Venereol* 1999; 79: 98–104.
95. Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. The release of histamine is associated with the inactivation of mast cell chymase during immediate allergic wheal reaction in the skin. *Clin Exp Allergy* 2001; 31: 593–601.
96. He S, Walls AF. Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. *Br J Pharmacol* 1998; 125: 1491–1500.
97. Tani K, Ogushi F, Kido H, Kawano T, Kunori Y, Kamimura T, et al. Chymase is a potent chemoattractant for human monocytes and neutrophils. *J Leukoc Biol* 2000; 67: 585–589.
98. Terakawa M, Tomimori Y, Goto M, Fukuda Y. Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils. *Eur J Pharmacol* 2006; 538: 175–181.
99. Mizutani H, Schechter NM, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1 β (IL-1 β) to an active IL-1 species by human mast cell chymase. *J Exp Med* 1991; 174: 821–825.
100. Omoto Y, Tokime K, Yamanaka K, Habe K, Morioka T, Kurokawa I, et al. Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. *J Immunol* 2006; 177: 8315–8319.
101. Cui P, Tani K, Kitamura H, Okumura Y, Yano M, Inui D, et al. A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. *J Leukoc Biol* 2001; 70: 306–312.
102. Zhao W, Oskeritzian CA, Pozez AL, Schwartz LB. Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. *J Immunol* 2005; 175: 2635–2642.
103. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. *J Pharmacol Exp Ther* 1988; 244: 133–137.
104. Diaconu N-C, Rummukainen J, Naukkarinen A, Mättö M, Harvima RJ, Pelkonen J, et al. Mast cell chymase is present in uterine cervical carcinoma and it detaches viable and growing cervical squamous carcinoma cells from substratum in vitro. *Arch Dermatol Res* 2011 Jan 29. [Epub ahead of print].
105. Hershko AY, Rivera J. Mast cell and T cell communication: an amplification and control of adaptive immunity. *Immunol Lett* 2010; 128: 98–104.
106. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: importance of mast cell-derived TNF. *Proc Natl Acad Sci USA* 2005; 102: 6467–6472.
107. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. *J Immunol* 2006; 176: 2238–2248.
108. Kashiwakura J, Yokoi H, Saito H, Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. *J Immunol* 2004; 173: 5247–5257.
109. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor α , which induces endothelial leukocyte adhesion molecule 1. *Proc Natl Acad Sci USA* 1991; 88: 4220–4224.
110. Ackermann L, Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF- α and their degranulation is associated with expression of ICAM-1 in the epidermis. *Arch Dermatol Res* 1998; 290: 353–359.
111. Diaconu N-C, Kaminska R, Naukkarinen A, Harvima RJ, Nilsson G, Harvima IT. Increase in CD30 ligand/CD153 and TNF- α expressing mast cells in basal cell carcinoma. *Cancer Immunol Immunother* 2007; 56: 1407–1415.
112. Piconese S, Gri G, Tripodo C, Musio S, Gorzanelli A, Frossi B, et al. Mast cells counteract regulatory T cell suppression through interleukin-6 and OX40/OX40L axis toward Th17 cell differentiation. *Blood* 2009; 114: 2639–2648.
113. Nakae S, Suto H, Berry GJ, Galli SJ. Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. *Blood* 2008; 109: 3640–3648.
114. Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G, et al. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. *J Exp Med* 2000; 192: 1441–1452.
115. Horsmanheimo L, Harvima IT, Järvikallio A, Harvima RJ, Naukkarinen A, Horsmanheimo M. Mast cells are one major source of interleukin-4 in atopic dermatitis. *Br J Dermatol* 1994; 131: 348–353.
116. Ackermann L, Harvima IT, Pelkonen J, Ritämäki-Salo V, Naukkarinen A, Harvima RJ, et al. Mast cells in psoriatic skin are strongly positive for interferon-gamma. *Br J Dermatol* 1999; 140: 624–633.
117. Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. Interleukin-4-positive mast cells are highly

- associated with the extent of immediate allergic wheal reaction in the skin. *Allergy* 2001; 56: 58–64. (Erratum: *Allergy* 2001; 56: 451.)
118. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. *Br J Haematol* 2001; 114: 616–623.
 119. Bengtsson Å, Scheynius A, Avila-Cariño J. Crosslinking of CD30 on activated human Th clones enhances their cytokine production and downregulates the CD30 expression. *Scand J Immunol* 2000; 52: 595–601.
 120. Poncet P, Arock M, David B. MHC class II-dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation. *J Leukoc Biol* 1999; 66: 105–112.
 121. Arock M, Ross E, Lai-Kuen R, Averlant G, Gao Z, Abraham SM. Phagocytic and tumor necrosis factor alpha response of human mast cells following exposure to gram-negative and gram-positive bacteria. *Infect Immun* 1998; 66: 6030–6034.
 122. Frandji P, Tkaczyk C, Oskeritzian C, David B, Desaymard C, Mécheri S. Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. *Eur J Immunol* 1996; 26: 2517–2528.
 123. Ghannadan M, Baghestanian M, Wimazal F, Eisenmenger M, Latal D, Kargül G, et al. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. *J Invest Dermatol* 1998; 111: 689–695.
 124. Inamura H, Kurosawa M, Kuwasaki T, Kamada Y, Kayaba H, Chihara J. Expression of adhesion molecules on cord-blood-derived, cultured human mast cells and effect of dexamethasone on intercellular adhesion molecule-1 expression on the mast cells treated by phorbol myristate acetate. *Allergy* 2001; 56: 672–678.
 125. Brill A, Baram D, Sela U, Salamon P, Mekori YA, Hershkoviz R. Induction of mast cell interactions with blood vessel wall components by direct contact with intact T cells or T cell membranes in vitro. *Clin Exp Allergy* 2004; 34: 1725–1731.
 126. Wang H-W, Tedla N, Lloyd AR, Wakefield D, McNeil HP. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. *J Clin Invest* 1998; 102: 1617–1626.
 127. McLachlan JB, Hart JP, Pizzo SV, Shelburne CP, Staats HF, Gunn MD, et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. *Nat Immunol* 2003; 4: 1199–1205.
 128. Jawdat DM, Rowden G, Marshall JS. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. *J Immunol* 2006; 177: 1755–1762.
 129. Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF promotes dendritic cell migration. *J Immunol* 2006; 176: 4102–4112.
 130. Kitawaki T, Kadowaki N, Sugimoto N, Kambe N, Hori T, Miyachi Y, et al. IgE-activated mast cells in combination with pro-inflammatory factors induce Th2-promoting dendritic cells. *Int Immunol* 2006; 18: 1789–1799.
 131. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. *J Allergy Clin Immunol* 2003; 112: 15–22.
 132. Lu L-F, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. *Nature* 2006; 442: 997–1002.
 133. de Vries VC, Wasiuk A, Bennett KA, Benson MJ, Elgueta R, Waldschmidt TJ, et al. Mast cell degranulation breaks peripheral tolerance. *Am J Transplant* 2009; 9: 2270–2280.
 134. Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie ANJ, et al. IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. *J Immunol* 2009; 186: 83–91.
 135. Zhang W, Wu K, He W, Gao Y, Huang W, Lin X, et al. Transforming growth factor beta 1 plays an important role in inducing CD4+CD25+forkhead box P3+ regulatory T cells by mast cells. *Clin Exp Immunol* 2010; 161: 490–496.
 136. Forward NA, Furlong SJ, Yang Y, Lin T-J, Hoskin DW. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. *J Immunol* 2009; 183: 3014–3022.
 137. Grimbaldston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. *Nat Immunol* 2007; 8: 1095–1104.
 138. Biggs L, Yu C, Fedoric B, Lopez AF, Galli SJ, Grimbaldston MA. Evidence that vitamin D3 promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice. *J Exp Med* 2010; 207: 455–463.
 139. Byrne SN, Limón-Flores AL, Ullrich SE. Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression. *J Immunol* 2008; 180: 4648–4655.
 140. Limón-Flores AY, Chacón-Salinas R, Ramos G, Ullrich SE. Mast cells mediate the immune suppression induced by dermal exposure to JP-8 jet fuel. *Toxicol Sci* 2009; 112: 144–152.
 141. Depinay N, Hacini F, Beghdadi W, Peronet R, Mécheri S. Mast cell-dependent down-regulation of antigen-specific immune responses by mosquito bites. *J Immunol* 2006; 176: 4141–4146.
 142. Chacón-Salinas R, Limón-Flores AY, Chávez-Blanco AD, Gonzales-Estrada A, Ullrich SE. Mast cell-derived IL-10 suppresses germinal center formation by affecting T follicular helper cell function. *J Immunol* 2011; 186: 25–31.
 143. Ishizuka T, Okayama Y, Kobayashi H, Mori M. Interleukin-10 is localized to and released by human lung mast cells. *Clin Exp Allergy* 1999; 29: 1424–1432.
 144. Kanbe N, Kurosawa M, Nagata H, Saitoh H, Miyachi Y. Cord blood-derived human cultured mast cells produce transforming growth factor β 1. *Clin Exp Allergy* 1999; 29: 105–113.
 145. Royer B, Varadaradjalou S, Saas P, Gabiot AC, Kantelip B, Féger F, et al. Autocrine regulation of cord blood-derived human mast cell activation by IL-10. *J Allergy Clin Immunol* 2001; 108: 80–86.
 146. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. *Mod Pathol* 2006; 19: 149–159.
 147. Huang B, Lei Z, Zhang G-M, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. *Blood* 2008; 112: 1269–1279.
 148. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen G-X, et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. *PLoS ONE* 2010; 5: e8922.
 149. Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. *Proc Natl Acad Sci USA* 2010; 107: 6430–6435.